Provided are novel compounds of Formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.

The present invention is generally directed to novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and processes for their preparation.

The present invention is generally directed to novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and processes for their preparation.

This invention is directed to methods of preparing AQX-1125 having the formula: ##STR00001## This invention is also directed to intermediates utilized in the methods of preparing AQX-1125.

This invention is directed to methods of preparing AQX-1125 having the formula: ##STR00001## This invention is also directed to intermediates utilized in the methods of preparing AQX-1125.

The present invention relates to an improved process for preparing 3-(aminomethyl)-3,5,5-trimethylcyclohexanol, called isophorone amino alcohol (IPAA) hereinafter. In particular, the present invention is directed to a one-stage process for preparing 3-aminomethyl-3,5,5-trimethylcyclohexanol by hydrogenation of isophoronenitrile (IPN) with hydrogen over a catalyst, in the presence or absence of solvents, wherein the catalyst has certain properties.

The present invention relates to an improved process for preparing 3-(aminomethyl)-3,5,5-trimethylcyclohexanol, called isophorone amino alcohol (IPAA) hereinafter. In particular, the present invention is directed to a one-stage process for preparing 3-aminomethyl-3,5,5-trimethylcyclohexanol by hydrogenation of isophoronenitrile (IPN) with hydrogen over a catalyst, in the presence or absence of solvents, wherein the catalyst has certain properties.

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.